The initial price range for the IPO was $15-18, so evidently the demand for minority shares of a tiny ag-biotech company did not materialize to the extent the investment bankers expected.
CLLS is retaining approximately 80%* of Calyxt equity.
Calyxt has been discussed at length on iHub (e.g. thread starting at #msg-132441707).
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.